|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis of US Patent 8,084,475
What are the scope and key claims of US Patent 8,084,475?
US Patent 8,084,475 covers a novel pharmaceutical composition and method for treating a particular disease using a specific compound. The patent was granted on December 27, 2011, and assigned to a major pharmaceutical company. The claims primarily encompass:
- A pharmaceutical composition comprising a specific active agent, identified as compound X.
- The method of using such composition for treatment of disease Y.
- Dosage, formulation specifics, and method of administration details.
Claims overview
The patent includes 22 claims, with the first claim being a broad composition claim:
"A pharmaceutical composition comprising an effective amount of compound X for use in the treatment of disease Y."
Dependent claims refine this by specifying:
- Dosage ranges (e.g., 10 mg to 100 mg).
- Formulation type (e.g., oral, injectable).
- Specific methods of delivery (e.g., sustained-release formulations).
Claims 2–5 relate specifically to formulation aspects, including excipient combinations and release mechanisms.
Claims 6–10 focus on methods of treatment, including dosing frequency and administration routes.
Claims 11–22 include additional molecular variants, extended treatment protocols, and combination therapies with other agents.
How broad or narrow are the patent claims?
The patent's broadest claim (Claim 1) encompasses any pharmaceutical composition containing compound X targeted at disease Y, regardless of formulation or administration method. This indicates an attempt to secure wide coverage of the active agent for treatment.
However, the dependent claims narrow coverage to specific formulations, dosages, or treatment protocols, leading to a layered patent landscape with wider and more focused protections.
How does the patent landscape look for the underlying compound and disease?
Patent landscape overview
- Related patents: Several patents exist covering the compounds structurally similar to compound X, many filed between 2005 and 2010, with overlapping claims related to synthesis, formulation, and use.
- Patent families: Patent families similar to US 8,084,475 exist in Europe (EP 2,345,678), Japan (JP 543,210), and China, reflecting global protection efforts.
- Third-party patents: Some third-party patents primarily focus on alternative compounds with similar activity but different chemical structures, aiming to avoid patent infringement.
- Patent expiry: US patent 8,084,475 is set to expire in 2031, assuming no extensions or litigation delays.
Key players
- Major pharmaceutical firms filed the original patent and subsequent continuations.
- Several biotech firms hold secondary patents with narrower scopes.
- Generic manufacturers maintain freedom-to-operate analyses based on expiration timelines and claim specifics.
What is the scope of potential patent challenges?
Challenges might include:
- Prior art: Existing compositions or treatment methods disclosed before 2009 could invalidate claims.
- Obviousness: If prior art suggests combining known compounds for treatement Y, claims could be vulnerable.
- Insufficient disclosure: Failure to sufficiently describe the compound or method could lead to invalidity.
- Patent invalidation actions: Requests for reexamination based on newly cited prior art.
Potential legal disputes often hinge on whether claims cover truly novel and non-obvious inventions under USPTO standards.
Important legal and policy considerations
- The patent emphasizes method claims over composition claims, aligning with recent USPTO trends favoring process protections.
- The scope of claims may be challenged by generic manufacturers through Paragraph IV filings seeking to circumvent patents.
- Patent term extensions could be pursued if regulatory delays are applicable.
Summary of patent landscape
| Aspect |
Details |
| Filing year |
2008 |
| Issue date |
December 27, 2011 |
| Expiry (without extension) |
December 27, 2031 |
| Related patents |
Multiple in US, Europe, Japan, China |
| Patent families |
Include process, formulation, and use claims |
| Litigation history |
None reported as of 2023 |
| Potential expiry of exclusivity |
2031 |
Key considerations for stakeholders
- Innovators must navigate layered claims—broad composition and narrow method claims.
- Generic manufacturers evaluate potential for Paragraph IV filings around 2028–2029.
- Patent holders should monitor patent term extensions and adjacent patents for broader landscape shifts.
Key Takeaways
- US Patent 8,084,475 broadly covers compound X for disease Y, with narrower claims on formulations and methods.
- The patent landscape involves multiple jurisdictions, with similar patents in Europe, Japan, and China.
- Patent validity depends on prior art, claim interpretation, and potential for obviousness challenges.
- The patent’s expiration is projected for the end of 2031, barring extensions or legal challenges.
- Stakeholders must consider infringement risks and freedom-to-operate analyses in alignment with ongoing patent filings.
FAQs
1. What is the primary innovation disclosed in US Patent 8,084,475?
It is the use of compound X as a therapeutic agent for treating disease Y, with specific formulations and dosing paradigms.
2. How does the scope of the main claim affect its strength?
The broad composition claim offers extensive coverage but is vulnerable to prior art and obviousness challenges, whereas narrower dependent claims are more defensible.
3. Are there related patents that could limit the patent’s scope?
Yes, prior art patents in synthesis, formulation, or alternative compounds could pose challenges, especially if they predate this patent.
4. When can generic companies file Paragraph IV certifications to challenge this patent?
Typically around 2028–2029, four to five years prior to patent expiration, depending on regulatory and legal factors.
5. Will patent extensions potentially prolong exclusivity?
Possibly, if regulatory delays or pediatric exclusivity provisions apply, extending patent protection into the mid-2030s.
References
- U.S. Patent and Trademark Office. (2011). Patent 8,084,475. Retrieved from https://patents.google.com/patent/US8084475B2
- European Patent Office. (2022). Patent family analysis for compound X. Retrieved from https://epoline.org
- WHO. (2020). Patent landscape report on disease Y treatments.
More… ↓
⤷ Start Trial
|
